Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Corbus Pharmaceuticals Hldgs Inc (CRBP)

Corbus Pharmaceuticals Hldgs Inc (CRBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 227,752
  • Shares Outstanding, K 12,044
  • Annual Sales, $ 0 K
  • Annual Income, $ -44,600 K
  • EBIT $ -40 M
  • EBITDA $ -39 M
  • 60-Month Beta 2.56
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.56

Options Overview Details

View History
  • Implied Volatility 82.93% ( -8.24%)
  • Historical Volatility 52.95%
  • IV Percentile 16%
  • IV Rank 7.63%
  • IV High 222.54% on 09/19/24
  • IV Low 71.39% on 10/16/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 930
  • Volume Avg (30-Day) 850
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 13,502
  • Open Int (30-Day) 16,396

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.99
  • Number of Estimates 6
  • High Estimate -0.78
  • Low Estimate -1.14
  • Prior Year -2.27
  • Growth Rate Est. (year over year) +56.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.92 +18.78%
on 10/31/24
19.85 -4.74%
on 10/08/24
-0.30 (-1.56%)
since 10/04/24
3-Month
15.92 +18.78%
on 10/31/24
61.89 -69.45%
on 08/22/24
-34.03 (-64.28%)
since 08/06/24
52-Week
3.03 +523.39%
on 11/13/23
61.90 -69.45%
on 07/31/24
+13.87 (+275.20%)
since 11/06/23

Most Recent Stories

More News
Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update

CRBP : 18.91 (-1.25%)
Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

CRBP : 18.91 (-1.25%)
Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

CRBP : 18.91 (-1.25%)
Up 174% in 2024, Is It Too Late to Buy This Breakout Biotech Stock?

After more than doubling in the past year, is this clinical-stage biotech stock still a buy?

CRBP : 18.91 (-1.25%)
$SPX : 5,929.04 (+2.53%)
NVO : 105.36 (-4.33%)
MRK : 100.73 (-0.91%)
LLY : 776.38 (-3.68%)
ABBV : 201.20 (-0.24%)
PFE : 27.36 (-2.25%)
XBI : 102.44 (+1.81%)
BMY : 55.28 (-1.20%)
Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

CRBP : 18.91 (-1.25%)
Corbus Pharmaceuticals: Q2 Earnings Snapshot

Corbus Pharmaceuticals: Q2 Earnings Snapshot

CRBP : 18.91 (-1.25%)
Up Over 700% YTD, Here's How Much Higher Analysts Think This Biotech Stock Can Rise

As the biotech industry rebounds from recent challenges, a favorable regulatory environment and groundbreaking scientific advancements are creating investment opportunities, particularly in companies with...

CRBP : 18.91 (-1.25%)
Stocks Climb on Lower Bond Yields and Positive Corporate News

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.10%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.31%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.11%. US stocks this morning...

$SPX : 5,929.04 (+2.53%)
SPY : 591.04 (+2.49%)
$DOWI : 43,729.93 (+3.57%)
DIA : 437.23 (+3.54%)
$IUXX : 20,781.33 (+2.74%)
QQQ : 505.58 (+2.72%)
ZNZ24 : 109-175 (unch)
INCY : 80.95 (+4.75%)
AAPL : 222.72 (-0.33%)
WYNN : 85.32 (-1.61%)
LVS : 50.70 (+0.72%)
MGM : 37.43 (+3.31%)
Corbus Pharmaceuticals: Q1 Earnings Snapshot

Corbus Pharmaceuticals: Q1 Earnings Snapshot

CRBP : 18.91 (-1.25%)
Corbus Pharmaceuticals: Q4 Earnings Snapshot

Corbus Pharmaceuticals: Q4 Earnings Snapshot

CRBP : 18.91 (-1.25%)

Business Summary

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic...

See More

Key Turning Points

3rd Resistance Point 20.48
2nd Resistance Point 19.93
1st Resistance Point 19.42
Last Price 18.91
1st Support Level 18.37
2nd Support Level 17.82
3rd Support Level 17.31

See More

52-Week High 61.90
Fibonacci 61.8% 39.41
Fibonacci 50% 32.47
Fibonacci 38.2% 25.52
Last Price 18.91
52-Week Low 3.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar